2016
Characterizing Patients with Very-Low-Level HIV Viremia: A Community-Based Study
Helou E, Shenoi S, Kyriakides T, Landry ML, Kozal M, Barakat LA. Characterizing Patients with Very-Low-Level HIV Viremia: A Community-Based Study. Journal Of The International Association Of Providers Of AIDS Care (JIAPAC) 2016, 16: 261-266. PMID: 27903948, PMCID: PMC5423832, DOI: 10.1177/2325957416680028.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-HIV AgentsCD4 Lymphocyte CountFemaleHIV InfectionsHIV-1HumansMaleMiddle AgedViral LoadViremiaConceptsVirologic failureViral load levelsPill burdenAlcohol useHuman immunodeficiency virus (HIV) careLow-level HIV viremiaUndetectable viral load levelsAntiretroviral regimen changesAntiretroviral therapy changesExperienced virologic failureLow-level viremiaIntravenous drug useSubset of patientsFrequent clinic visitsPoor clinical outcomePossible risk factorsHepatitis C virusHIV viremiaMore comorbiditiesNonfailure groupVirologic suppressionVirological failureCD4 countConsecutive chartsClinic visits
2012
Predictive value of HIV‐1 replication capacity and phenotypic susceptibility scores in antiretroviral treatment‐experienced patients
Bedimo R, Kyriakides T, Brown S, Weidler J, Lie Y, Coakley E, Holodniy M. Predictive value of HIV‐1 replication capacity and phenotypic susceptibility scores in antiretroviral treatment‐experienced patients. HIV Medicine 2012, 13: 345-351. PMID: 22276745, DOI: 10.1111/j.1468-1293.2011.00981.x.Peer-Reviewed Original ResearchConceptsCD4 cell countViral load changesWeek 12Replication capacityPredictive valueCell countCD4 cell count responseHIV-1 replication capacityAntiretroviral treatment responseHIV replication capacityImmediate salvage therapyPhenotypic susceptibility scoresDrug-free periodPhenotypic resistance testingCell count responseAdditional predictive valueMultivariate regression analysisTreatment reinitiationSalvage therapyWeek 24ARV therapyViral loadPrognostic valueARV treatmentAntiretroviral trials
2011
Results of Antiretroviral Treatment Interruption and Intensification in Advanced Multi-Drug Resistant HIV Infection from the OPTIMA Trial
Holodniy M, Brown ST, Cameron DW, Kyriakides TC, Angus B, Babiker A, Singer J, Owens DK, Anis A, Goodall R, Hudson F, Piaseczny M, Russo J, Schechter M, Deyton L, Darbyshire J, . Results of Antiretroviral Treatment Interruption and Intensification in Advanced Multi-Drug Resistant HIV Infection from the OPTIMA Trial. PLOS ONE 2011, 6: e14764. PMID: 21483491, PMCID: PMC3069000, DOI: 10.1371/journal.pone.0014764.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-HIV AgentsDrug Resistance, Multiple, ViralFemaleHIV InfectionsHumansMaleMiddle AgedConceptsRe-treatment optionsART interruptionHIV infectionPrimary outcomeRetreatment optionsMultidrug resistanceAdvanced HIV diseaseAntiretroviral treatment interruptionARV treatment failurePrior AIDS diagnosisResistant HIV InfectionMedian CD4 countPrimary composite outcomeSerious adverse eventsMean viral loadBest medical managementOPTIMA trialCD4 countOpen labelTreatment interruptionAdverse eventsComposite outcomeFirst AIDSHIV diseaseAntiretroviral treatment
2010
Connection Domain Mutations in Treatment-Experienced Patients in the OPTIMA Trial
Dau B, Ayers D, Singer J, Harrigan PR, Brown S, Kyriakides T, Cameron DW, Angus B, Holodniy M. Connection Domain Mutations in Treatment-Experienced Patients in the OPTIMA Trial. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2010, 54: 160-166. PMID: 20130473, DOI: 10.1097/qai.0b013e3181cbd235.Peer-Reviewed Original ResearchConceptsTreatment-naive populationTreatment-experienced patientsCD mutationsTreatment-experienced populationsHIV viral loadConnection domainConnection domain mutationsOPTIMA trialVirologic outcomesVirologic responseARV regimenARV therapyViral loadAntiretroviral drugsAntiretroviral trialsUnivariate analysisDiminished responseFrequency of mutationsMultivariate analysisPatientsReduced susceptibilityA371VDomain mutationsResistance phenotypeTrials
2009
Quality of Life of Patients With Advanced HIV/AIDS: Measuring the Impact of Both AIDS-Defining Events and Non-AIDS Serious Adverse Events
Anis AH, Nosyk B, Sun H, Guh DP, Bansback N, Li X, Barnett PG, Joyce V, Swanson KM, Kyriakides TC, Holodniy M, Cameron DW, Brown ST. Quality of Life of Patients With Advanced HIV/AIDS: Measuring the Impact of Both AIDS-Defining Events and Non-AIDS Serious Adverse Events. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2009, 51: 631-639. PMID: 19430303, DOI: 10.1097/qai.0b013e3181a4f00d.Peer-Reviewed Original ResearchConceptsSerious adverse eventsLate-stage HIV/AIDSAdvanced HIV/AIDSHIV/AIDSAdverse eventsMedical Outcomes Study HIV Health SurveyMental health summary scoresEffect of ADEMultidrug-resistant HIVHealth-related qualityHealth summary scoresQuality of lifePatients' HRQOLMultivariate linear regression modelRegular followHRQOL measuresTreatment strategiesEQ-5DHealth SurveyHRQoLImmune diseasesSummary scoresPatientsStudy sample populationAIDSHealth-Related Quality of Life in a Randomized Trial of Antiretroviral Therapy for Advanced HIV Disease
Joyce VR, Barnett PG, Bayoumi AM, Griffin SC, Kyriakides TC, Yu W, Sundaram V, Holodniy M, Brown ST, Cameron W, Youle M, Sculpher M, Anis AH, Owens DK. Health-Related Quality of Life in a Randomized Trial of Antiretroviral Therapy for Advanced HIV Disease. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2009, 50: 27-36. PMID: 19295332, DOI: 10.1097/qai.0b013e31818ce6f3.Peer-Reviewed Original ResearchConceptsHealth Utilities Index Mark 3Treatment-experienced HIV patientsEQ-5DHIV patientsHRQoL scoresClinical variablesMedical Outcomes Study HIV Health SurveyEQ-5D visual analog scaleHealth statusStandard gamblePreference-based health-related qualityAdvanced HIV diseaseBaseline HRQOL scoresConcomitant medication useTreatment-experienced HIVCD4 cell countHIV viral loadHealth-related qualityVisual analog scaleVeterans Affairs hospitalEQ-5D VASCross-sectional studyPreference-based HRQOLQuality of lifeTime trade-off (TTO) technique
2007
Evolution of Genotypic Resistance Algorithms and Their Impact on the Interpretation of Clinical Trials: An OPTIMA Trial Substudy
Desai S, Kyriakides T, Holodniy M, Al-Salman J, Griffith B, Kozal M. Evolution of Genotypic Resistance Algorithms and Their Impact on the Interpretation of Clinical Trials: An OPTIMA Trial Substudy. HIV Research & Clinical Practice 2007, 8: 293-302. PMID: 17956830, DOI: 10.1310/hct0805-293.Peer-Reviewed Original ResearchConceptsLong-term clinical trialsGenotypic resistance algorithmsClinical trialsDisease progressionHIV disease progression ratesHIV-1 pol sequencesHIV disease progressionDisease progression rateResistance algorithmsVirologic responseDrug comparisonsProgression rateVirtual phenotypeGenotypic algorithmsPol sequencesPatientsDrug resistanceResistance interpretationTrialsProgressionDrugsExpected ratesViral sequencesFirst eventSimilar time
2003
An open-label randomized clinical trial of novel therapeutic strategies for HIV-infected patients in whom antiretroviral therapy has failed: rationale and design of the OPTIMA Trial
Kyriakides TC, Babiker A, Singer J, Cameron W, Schechter MT, Holodniy M, Brown ST, Youle M, Gazzard B, Team O. An open-label randomized clinical trial of novel therapeutic strategies for HIV-infected patients in whom antiretroviral therapy has failed: rationale and design of the OPTIMA Trial. Contemporary Clinical Trials 2003, 24: 481-500. PMID: 12865041, DOI: 10.1016/s0197-2456(03)00029-1.Peer-Reviewed Original ResearchConceptsOPTIMA trialClinical trialsTherapeutic strategiesHuman immunodeficiency virus-infected individualsVirus-infected individualsDrug-free periodVeterans Affairs hospitalDifferent therapeutic strategiesYears of intakeNovel therapeutic strategiesAnti-HIV drugsAntiretroviral therapyStrategy armART drugsTrial designHIV drugsStudy durationHospitalTrialsRelative efficacyDrugsTherapyOptimum trial designYearsMulticenter
2001
Development and Application of a Genotypic AZT Resistance Assay: Quantitative Assessment of the Resistance Profile of Clinical Samples and the Relative Predictive Ability of a Resistance Index.
Kyriakides TC, Heimer RR. Development and Application of a Genotypic AZT Resistance Assay: Quantitative Assessment of the Resistance Profile of Clinical Samples and the Relative Predictive Ability of a Resistance Index. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2001, 28: 211. PMID: 11694826, DOI: 10.1097/00042560-200111010-00002.Peer-Reviewed Original ResearchConceptsViral loadCD4 countResistance indexAZT resistanceResistance profilesBaseline viral loadHIV disease progressionLigase chain reaction assayMonths of treatmentWild-type HIV-1Resistance assaysAntiretroviral therapyDisease progressionSurrogate markerChain reaction assaysHIV-1PatientsAZTPredictive abilityClinical samplesReaction assaysCountAssaysRelative predictive abilityFurther supportTiming of Antiretroviral Treatment Initiation
Kyriakides T, Guarino P. Timing of Antiretroviral Treatment Initiation. JAMA 2001, 285: 1702-1703. PMID: 11277817, DOI: 10.1001/jama.285.13.1702.Peer-Reviewed Original Research